MA30482B1 - Sels et leurs modification cristallines - Google Patents

Sels et leurs modification cristallines

Info

Publication number
MA30482B1
MA30482B1 MA31419A MA31419A MA30482B1 MA 30482 B1 MA30482 B1 MA 30482B1 MA 31419 A MA31419 A MA 31419A MA 31419 A MA31419 A MA 31419A MA 30482 B1 MA30482 B1 MA 30482B1
Authority
MA
Morocco
Prior art keywords
salts
crystalline modification
phenyl
crystalline forms
diazepin
Prior art date
Application number
MA31419A
Other languages
English (en)
Inventor
Lili Feng
Xinglong Jiang
Piotr Karpinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30482B1 publication Critical patent/MA30482B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des sels de 1-(2-fluoro-phényl)-3-(2-oxo-5-phényl-2,3-dihydro-lH-benzo[e][l,4]diazépin-3-yl)-urée et leurs formes cristallines, leur production et leur utilisation, ainsi que des préparations pharmaceutiques contenant de tels sels et de telles formes cristallines.
MA31419A 2006-05-23 2008-11-26 Sels et leurs modification cristallines MA30482B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80283606P 2006-05-23 2006-05-23

Publications (1)

Publication Number Publication Date
MA30482B1 true MA30482B1 (fr) 2009-06-01

Family

ID=38704747

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31419A MA30482B1 (fr) 2006-05-23 2008-11-26 Sels et leurs modification cristallines

Country Status (28)

Country Link
US (1) US7977330B2 (fr)
EP (1) EP2029556B1 (fr)
JP (2) JP2009538330A (fr)
KR (1) KR20090009898A (fr)
CN (1) CN101448796B (fr)
AR (1) AR061056A1 (fr)
AT (1) ATE486858T1 (fr)
AU (1) AU2007267671A1 (fr)
BR (1) BRPI0712556A2 (fr)
CA (1) CA2650514A1 (fr)
CL (1) CL2007001454A1 (fr)
CR (1) CR10431A (fr)
DE (1) DE602007010286D1 (fr)
EC (1) ECSP088900A (fr)
ES (1) ES2355166T3 (fr)
GT (1) GT200800253A (fr)
IL (1) IL195008A0 (fr)
MA (1) MA30482B1 (fr)
MX (1) MX2008014836A (fr)
NO (1) NO20085000L (fr)
PE (1) PE20080261A1 (fr)
PL (1) PL2029556T3 (fr)
PT (1) PT2029556E (fr)
RU (1) RU2008150627A (fr)
TN (1) TNSN08477A1 (fr)
TW (1) TW200815375A (fr)
WO (1) WO2007140154A2 (fr)
ZA (1) ZA200809096B (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012387B1 (ru) * 2002-09-20 2009-10-30 Эрроу Терапьютикс Лимитед Производные бензодиазепина, содержащие их продукт и фармацевтическая композиция и их применение

Also Published As

Publication number Publication date
IL195008A0 (en) 2009-08-03
ATE486858T1 (de) 2010-11-15
CN101448796A (zh) 2009-06-03
US20090163478A1 (en) 2009-06-25
DE602007010286D1 (de) 2010-12-16
EP2029556A2 (fr) 2009-03-04
AR061056A1 (es) 2008-07-30
TNSN08477A1 (en) 2010-04-14
PE20080261A1 (es) 2008-04-18
CL2007001454A1 (es) 2008-05-16
EP2029556B1 (fr) 2010-11-03
CN101448796B (zh) 2012-09-26
WO2007140154A3 (fr) 2008-03-20
MX2008014836A (es) 2008-12-01
BRPI0712556A2 (pt) 2013-07-02
AU2007267671A1 (en) 2007-12-06
WO2007140154A2 (fr) 2007-12-06
JP2009538330A (ja) 2009-11-05
KR20090009898A (ko) 2009-01-23
JP2013075910A (ja) 2013-04-25
ES2355166T3 (es) 2011-03-23
RU2008150627A (ru) 2010-06-27
GT200800253A (es) 2009-04-29
CA2650514A1 (fr) 2007-12-06
TW200815375A (en) 2008-04-01
NO20085000L (no) 2008-12-23
PL2029556T3 (pl) 2011-04-29
PT2029556E (pt) 2011-01-31
ZA200809096B (en) 2009-11-25
ECSP088900A (es) 2008-12-30
CR10431A (es) 2009-01-07
US7977330B2 (en) 2011-07-12

Similar Documents

Publication Publication Date Title
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
MA30766B1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
TNSN08140A1 (fr)
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
BR0110961A (pt) Derivados de triazol
MA29816B1 (fr) Composes de benzimidazole thiophene
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
ME00155B (me) 5-SUPSTITUISANI HINOLIN I IZOHINOLIN DERIVATI, POSTUPAK NJIHOVE PROIZVODNJE l NJIHOVA UPOTREBA KAO ANTI-INFLAMATORNIH SREDSTAVA
MA31167B1 (fr) Inhibiteurs de l'activite de akt
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
PE20081506A1 (es) Formulaciones de ansamicina
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MA31305B1 (fr) Administration hebdomadaire d'inhibiteurs de la dipeptidyle peptidase
MY149422A (en) 5-(arylsulfonyl)-pyrazolopiperidines
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
NO20064808L (no) Orale matrixformuleringer med licarbazepin
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
ATE459600T1 (de) Substituierte pyrrolidin-2-one